-+ 0.00%
-+ 0.00%
-+ 0.00%

Atossa says Phase 2 EVANGELINE trial tests (Z)-endoxifen plus goserelin in premenopausal ER+/HER2- breast cancer

PUBT·05/27/2026 12:32:04
Listen to the news
Atossa says Phase 2 EVANGELINE trial tests (Z)-endoxifen plus goserelin in premenopausal ER+/HER2- breast cancer
  • Atossa Therapeutics announced two (Z)-endoxifen abstracts accepted for ASCO 2026, with presentations scheduled May 29 to June 2 in Chicago.
  • New preclinical findings will be presented, supporting (Z)-endoxifen activity in models linked to endocrine-resistant ER-positive breast cancer.
  • A trial-in-progress poster will outline the ongoing Phase 2 EVANGELINE study of (Z)-endoxifen with goserelin in premenopausal ER+/HER2- breast cancer.
  • The study is designed to gauge early anti-tumor effect before surgery, with broader readouts intended to inform further development decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF68315) on May 27, 2026, and is solely responsible for the information contained therein.